Literature DB >> 22519600

β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.

Mahipal G Sinnollareddy1, Michael S Roberts, Jeffrey Lipman, Jason A Roberts.   

Abstract

1. Infections and related sepsis are two of the most prevalent issues in the care of critically ill patients, with mortality as high as 70%. Appropriate antibiotic selection, as well as adequate dosing, is important to improve the clinical outcome for these patients. 2. β-Lactams are the most common antibiotic class used in critically ill sepsis patients because of their broad spectrum of activity and high tolerability. β-Lactams exhibit time-dependent antibacterial activity. Therefore, concentrations need to be maintained above the minimum inhibitory concentration (MIC) of pathogenic bacteria. β-Lactams are hydrophilic antibiotics with small distribution volumes similar to extracellular water and are predominantly excreted through the renal system. 3. Critically ill patients experience a myriad of physiological changes that result in changes in the pharmacokinetics (PK) of hydrophilic drugs such as β-lactams. A different approach to dosing with β-lactams may increase the likelihood of positive outcomes considering the pharmacodynamics (PD) of β-lactams, as well as the changes in PK in critically ill patients. 4. The present review describes the strategies for dose optimization of β-lactams in critically ill patients in line with the PK and PD of these drugs.
© 2012 The Authors Clinical and Experimental Pharmacology and Physiology © 2012 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22519600     DOI: 10.1111/j.1440-1681.2012.05715.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  17 in total

1.  After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients.

Authors:  Katharina Olbrisch; Tobias Kisch; Julia Thern; Evelyn Kramme; Jan Rupp; Tobias Graf; Sebastian G Wicha; Peter Mailänder; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-27       Impact factor: 3.000

2.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

3.  Is there a role for continuous infusion of β-lactam antibiotics in severe sepsis?

Authors:  Angela Bates; Ari R Joffe
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

4.  Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial.

Authors:  Ilona Nowak-Kózka; Kamil J Polok; Jacek Górka; Jakub Fronczek; Anna Gielicz; Bożena Seczyńska; Mirosław Czuczwar; Bartosz Kudliński; Wojciech Szczeklik
Journal:  Pharmacol Rep       Date:  2020-01-04       Impact factor: 3.024

Review 5.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

6.  In Vitro Resistance Selection in Shigella flexneri by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin.

Authors:  George P Allen; Kayla A Harris
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

7.  Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy.

Authors:  J Petersson; C G Giske; E Eliasson
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

8.  Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.

Authors:  Francesca Mattioli; Carmen Fucile; Valerio Del Bono; Valeria Marini; Andrea Parisini; Alexandre Molin; Maria Laura Zuccoli; Giulia Milano; Romano Danesi; Anna Marchese; Marialuisa Polillo; Claudio Viscoli; Paolo Pelosi; Antonietta Martelli; Antonello Di Paolo
Journal:  Eur J Clin Pharmacol       Date:  2016-04-06       Impact factor: 2.953

9.  Continuous beta-lactam infusion in critically ill patients: the clinical evidence.

Authors:  Mohd H Abdul-Aziz; Joel M Dulhunty; Rinaldo Bellomo; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-08-16       Impact factor: 6.925

10.  Clinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot Study.

Authors:  Aiping Wen; Zhe Li; Junxian Yu; Ren Li; Sheng Cheng; Meili Duan; Jing Bai
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.